Other therapeutic strategies correspond to the standard of care of non-SDB patients with heart failure (e.g., angiotensin-converting enzyme inhibitors, angiotensin receptor–neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, gliflozins, etc.)or atrial fibrillation (e.g., beta-blockers, calcium channel antagonists, digitalis glycosides, amiodarone, anticoagulation, etc.)[49,50]. The gene discussed is NR3C2; the disease is atrial fibrillation.